Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis von Voshaar, M J H, van den Bemt, B J F, van de Laar, M A F J, van Dulmen, A M, Vriezekolk, J E

Volltext

Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM... von Steunebrink, L M M, Versteeg, G A, Vonkeman, H E, Ten Klooster, P M, Kuper, H H, Zijlstra, T R, van Riel, P L C M, van de Laar, M A F J

Volltext

Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study von Meek, I. L., Vonkeman, H. E., Kasemier, J., Movig, K. L. L., van de Laar, M. A. F. J.

Volltext

Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice von Versteeg, G. A., Steunebrink, L. M. M., Vonkeman, H. E., ten Klooster, P. M., van der Bijl, A. E., van de Laar, M. A. F. J.

Volltext

Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise von Voshaar, M. J. H., Vriezekolk, J. E., van Dulmen, A. M., van den Bemt, B. J. F., van de Laar, M. A. F. J.

Volltext

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout von Reinders, M K, Haagsma, C, Jansen, T L Th A, van Roon, E N, Delsing, J, van de Laar, M A F J, Brouwers, J R B J

Volltext

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperur... von Janssen, C. A., Oude Voshaar, M. A. H., Vonkeman, H. E., Krol, M., van de Laar, M. A. F. J.

Volltext

Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry von Arts, E E A, Jansen, T L, Broeder, A Den, Vonkeman, H E, Dutmer, E, Van de Laar, M A F J, Van Riel, P L C M, Fransen, J

Volltext

Patient-centred care in established rheumatoid arthritis von Voshaar, M.J.H., MSc, Nota, I., MSc, van de Laar, M.A.F.J., MD, PhD, van den Bemt, B.J.F., PharmD, PhD

Volltext

Efficacy of serology driven “test and treat strategy” for eradication of H. pylori in patients with rheumatic disease in the Netherlands von de Leest, H. T. J. I., Steen, K. S. S., Lems, W. F., van de Laar, M. A. F. J., Huisman, A. M., Kadir, S. W., Houben, H. H. M. L., Kostense, P. J., Kuipers, E. J., Dijkmans, B. A. C., Debets-Ossenkopp, Y. J.

Volltext

Incidence and sources of native and prosthetic joint infection: a community based prospective survey von Kaandorp, Carola J E, Dinant, Huibert J, van de Laar, Mart A F J, Moens, Hein J Bernelot, Prins, A Pieter A, Dijkmans, Ben A C

Volltext

Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation von Van Roon, E. N., Hoekstra, M., Tobi, H., Jansen, T. L. TH. A., Bernelot Moens, H. J., Brouwers, J. R. B. J., Van De Laar, M. A. F. J.

Volltext

Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategie... von Kievit, W, Fransen, J, Adang, E M, Kuper, H H, Jansen, T L, De Gendt, C M A, De Rooij, D J R A M, Brus, H L M, van de Laar, M A F J, Van Riel, P C L M

Volltext

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis von Franke, L C, Ament, A J H A, van de Laar, M A F J, Boonen, A, Severens, J L

Volltext

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis von Hoekstra, M, van Ede, A E, Haagsma, C J, van de Laar, M A F J, Huizinga, T W J, Kruijsen, M W M, Laan, R F J M

Volltext

Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice von Blom, M., Kievit, W., Kuper, H. H., Jansen, T. L., Visser, H., den Broeder, A. A., Brus, H. L. M., van de Laar, M. A. F. J., van Riel, P. L. C. M.

Volltext

Coping with somatic illnesses in online support groups: Do the feared disadvantages actually occur? von van Uden-Kraan, C.F., Drossaert, C.H.C., Taal, E., Lebrun, C.E.I., Drossaers-Bakker, K.W., Smit, W.M., Seydel, E.R., van de Laar, M.A.F.J.

Volltext

Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists von Vroom, F., Van De Laar, M.A.J.F., Van Roon, E.N., Brouwers, J.R.B.J., De Jong-van den Berg, L.T.W.

Volltext

Can we assess baseline pain and global health retrospectively? von TEN KLOOSTER, P. M, DROSSAERS-BAKKER, K. W, TAAL, E, VAN DE LAAR, M. A. F. J

Volltext

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis von van Roon, E N, Jansen, T L T A, van de Laar, M A F J, Janssen, M, Yska, J P, Keuper, R, Houtman, P M, Brouwers, J R B J

Volltext